SCHEMBL2502722

SCHEMBL2502722

Cc1ccc(C(=O)O)c(C)c1C1CC1

nearest known ligand 0.42

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MAPT P10636 1/20 0.42
KDM4E B2RXH2 2/20 0.40
ALDH1A1 P00352 1/20 0.40
HPGD P15428 1/20 0.40
HSD17B10 Q99714 1/20 0.40
HAAO P46952 1/20 0.38
PTGER4 P35408 1/20 0.37
CYP1A2 P05177 1/20 0.37
GRM1 Q13255 1/20 0.37
NOTUM Q6P988 3/20 0.36
GPR35 Q9HC97 2/20 0.36
TSHR P16473 2/20 0.35
GAA P10253 1/20 0.35
SELL P14151 1/20 0.35
SELP P16109 1/20 0.35
MCL1 Q07820 1/20 0.35
CYP3A4 P08684 1/20 0.35
CYP2C9 P11712 1/20 0.35
KMT2A Q03164 1/20 0.35
POLB P06746 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL25436217 0.84 SIRT3 (0.37) MAPTKDM4EALDH1A1CYP3A4CYP2C9
SCHEMBL27764635 0.80 MAPT (0.41) MAPTKDM4EALDH1A1HPGDHSD17B10
SCHEMBL2499683 0.80 POLB (0.40) MAPTKDM4EALDH1A1HPGDCYP1A2
SCHEMBL2498153 0.80 MAPT (0.38) MAPTPTGER4CYP1A2NOTUMGPR35
SCHEMBL16762134 0.78 TAS2R14 (0.40) MAPTKDM4EALDH1A1HPGDHSD17B10
SCHEMBL2499752 0.78 GRM1 (0.39) MAPTKDM4EALDH1A1CYP1A2GRM1
SCHEMBL2505142 0.78 MAPT (0.37) MAPTCYP1A2NOTUMGPR35TSHR
SCHEMBL29056921 0.78 ALDH1A1 (0.58) MAPTKDM4EALDH1A1HPGDHSD17B10
SCHEMBL7080684 0.78 CYP1A2 (0.48) MAPTKDM4EALDH1A1HPGDCYP1A2
SCHEMBL5517327 0.76 ACMSD (0.43) MAPTKDM4EALDH1A1HPGDHSD17B10

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1813613-B1 NOVEL FUSED IMIDAZOLE DERIVATIVE MSD KK (JP) 2012-12-19 EP disclosed
US-8030327-B2 3-[1-(2-chlorophenyl)ethoxy]-5-imidazo[1,2-a]pyridin-3-ylthiophene-2-carboxyamide; polo like kinase inhibitor; antitumor and anticarcinogenic agent; mitotic phase (M phase) of the cell cycle MDS K.K. (JP) 2011-10-04 US disclosed
US-20080103136-A1 Novel Fused Imidazole Derivative MSD K.K. (JP) 2008-05-01 US disclosed
EP-1813613-A1 NOVEL FUSED IMIDAZOLE DERIVATIVE BANYU PHARMACEUTICAL CO., LTD. (JP) 2007-08-01 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080103136-A1 Novel Fused Imidazole Derivative HRH4, H1-4, H1-3 MAPT 4346/4885KDM4E 1299/4885ALDH1A1 1939/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.